DNLI
Price
$18.40
Change
+$0.13 (+0.71%)
Updated
Jan 15, 11:22 AM (EDT)
Capitalization
2.85B
46 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$6.58
Change
-$0.23 (-3.37%)
Updated
Jan 15, 12:21 PM (EDT)
Capitalization
948.14M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs VIR

Header iconDNLI vs VIR Comparison
Open Charts DNLI vs VIRBanner chart's image
Denali Therapeutics
Price$18.40
Change+$0.13 (+0.71%)
Volume$200
Capitalization2.85B
Vir Biotechnology
Price$6.58
Change-$0.23 (-3.37%)
Volume$300
Capitalization948.14M
DNLI vs VIR Comparison Chart in %
View a ticker or compare two or three
VS
DNLI vs. VIR commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and VIR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (DNLI: $18.27 vs. VIR: $6.82)
Brand notoriety: DNLI and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 72% vs. VIR: 162%
Market capitalization -- DNLI: $2.85B vs. VIR: $948.14M
DNLI [@Biotechnology] is valued at $2.85B. VIR’s [@Biotechnology] market capitalization is $948.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • VIR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VIR is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +7.79% price change this week, while VIR (@Biotechnology) price change was +10.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

VIR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.85B) has a higher market cap than VIR($948M). VIR YTD gains are higher at: 13.101 vs. DNLI (10.660). DNLI (-534.17M) and VIR (-541.01M) have comparable annual earnings (EBITDA) . DNLI has more cash in the bank: 848M vs. VIR (507M). DNLI has less debt than VIR: DNLI (44.4M) vs VIR (100M). VIR has higher revenues than DNLI: VIR (14M) vs DNLI (0).
DNLIVIRDNLI / VIR
Capitalization2.85B948M301%
EBITDA-534.17M-541.01M99%
Gain YTD10.66013.10181%
P/E RatioN/AN/A-
Revenue014M-
Total Cash848M507M167%
Total Debt44.4M100M44%
FUNDAMENTALS RATINGS
DNLI vs VIR: Fundamental Ratings
DNLI
VIR
OUTLOOK RATING
1..100
1461
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5061
P/E GROWTH RATING
1..100
9928
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIR's Valuation (52) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than DNLI’s over the last 12 months.

VIR's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that VIR’s stock grew similarly to DNLI’s over the last 12 months.

VIR's SMR Rating (97) in the null industry is in the same range as DNLI (97) in the Biotechnology industry. This means that VIR’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (50) in the Biotechnology industry is in the same range as VIR (61) in the null industry. This means that DNLI’s stock grew similarly to VIR’s over the last 12 months.

VIR's P/E Growth Rating (28) in the null industry is significantly better than the same rating for DNLI (99) in the Biotechnology industry. This means that VIR’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIVIR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYMCX8.580.07
+0.82%
Royce Micro-Cap Consult
JTUAX18.770.12
+0.64%
JPMorgan US Small Company A
TSCGX19.42-0.02
-0.10%
Thrivent Small Cap Growth S
ETTGX133.07-0.99
-0.74%
Eaton Vance Tx-Mgd Growth 1.1 A
JGRJX37.38-0.51
-1.35%
JPMorgan Growth Advantage R2

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.88%
RGNX - DNLI
54%
Loosely correlated
-0.66%
BEAM - DNLI
53%
Loosely correlated
+2.49%
VIR - DNLI
53%
Loosely correlated
+8.08%
SYRE - DNLI
52%
Loosely correlated
+5.17%
CDXS - DNLI
51%
Loosely correlated
+4.09%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been closely correlated with SANA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VIR jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
+8.08%
SANA - VIR
69%
Closely correlated
+0.85%
XNCR - VIR
54%
Loosely correlated
+3.66%
XENE - VIR
52%
Loosely correlated
+3.02%
NUVL - VIR
52%
Loosely correlated
+6.59%
CRBU - VIR
51%
Loosely correlated
+1.26%
More